This study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, an inherited eye disease that causes vision loss. The treatment aims to improve vision in low light by replacing a faulty gene. Participants receive either a low or high dos…
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC